Mirtazapine in combination with amitriptyline: A drug-drug interaction study in healthy subjects

Human Psychopharmacology

Volumn 18, Issue 2, 2003, Pages 91-101

  Sennef, C ^a   Timmer, C J ^a   Sitsen, J M A ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Amitriptyline; Cytochrome P450; Drug drug interaction; Mirtazapine

Indexed keywords

AMITRIPTYLINE; DEXTROMETHORPHAN; MIRTAZAPINE; PLACEBO;

ABDOMINAL DISCOMFORT; ADULT; ALERTNESS; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; ATTENTION; BLOOD ANALYSIS; CLINICAL TRIAL; COMPUTER; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TOLERABILITY; DYSARTHRIA; FATIGUE; FEMALE; GENDER; HEADACHE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PERFORMANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOMETRY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF CONCEPT; SINGLE BLIND PROCEDURE; SINUS TACHYCARDIA; SLEEP; SOMNOLENCE; STEADY STATE; TELEPHONE; TREMOR; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

ADOLESCENT; ADULT; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ATTENTION; COGNITION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MENTAL PROCESSES; MIANSERIN; PSYCHOMOTOR PERFORMANCE; SINGLE-BLIND METHOD;

EID: 0037338378     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.441     Document Type: Article

References (30)

1. Baer L, Brown-Beasley MW, Sorce J, Henriques AI. 1993. Computer-assisted telephone administration of a structured interview for obsessive-compulsive disorder. Am J Psychiatry 150: 1737-1738.
2. Baker EL, Letz R. 1986. Neurobehavioral testing in monitoring hazardous workplace exposures. J Occupat Med 28: 987-990.
3. Bond A, Lader M. 1974. The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211-218.
4. Ciminera JL, Bolognese JA, Gregg MH. 1987. The statistical evaluation of a three-period two-treatment crossover pharmacokinetic drug interaction study. Biometrics 43: 713-718.
5. Dahl M-L, Voortman G, Alm C, et al. 1997. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest 13: 37-46.
6. Davis R, Wilde MI. 1996. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs 5: 389-402.
7. De Boer T. 1996. The psychopharmacological profile of mirtazapine. J Clin Psychiatry 57(Suppl. 4): 19-25.
8. Delbressine LPC, Moonen MEG, Kaspersen FM, et al. 1998. Pharmaocokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Invest 15: 45-55.
9. Frackiewicz EJ, Sramek J, Cutler NR. 2000. Gender differences in depression and antidepressant pharmacokinetics and adverse events. Ann Pharmacother 34: 80-88.
10. 450 mediating N-demethylation of amitriptyline. Br J Clin Pharmacol 43: 137-144.
11. Holm KJ, Markham A. 1999. Mirtazapine: a review of its use in major depression. Drugs 57: 607-631.
12. Joffe RT. 1999. Substitution therapy in patients with major depression. CNS Drugs 11: 175-180.
13. Maris FA, Dingler E, Niehues S. 1999. High performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its demethyl metabolite in human plasma. J Chromatography B 721: 309-316.
14. Mattila M, Mattila MJ, Vrijmoed-deVries M, Kuitunen T. 1989. Actions and interactions of psychotropic drugs on human performance and mood: single doses of Org 3770, amitriptyline and diazepam. Pharmacol Toxicol 65: 81-88.
15. Montgomery SA. 1995. Safety of mirtazapine: a review. Int Clin Psychopharmacol 10: 37-45.
16. Nemeroff CB. 1997. Augmentation strategies in patients with refractory depression. Depression 4: 169-181.
17. Parrot AC, Hindmarch I. 1980. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopharmacology 71: 173-179.
18. Radhakishun FS, Van den Bos J, Van der Heijden BCJM, Roes KCB, O'Hanlon J. 2000. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol 20: 531-537.
19. Richelson E, Nelson A. 1984. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230: 94-102.
20. Ruwe FJL, Smulders RA, Kleijn HJ, Hartmans HLA, Sitsen JMA. 2001. A drug-drug interaction study with mirtazapine and paroxetine in healthy subjects. Hum Psychopharmacol 16: 449-459.
21. Sakulsripong M, Curran HV, Lader M. 1991. Does tolerance develop to the sedative and amnesic effects of antidepressants? A comparison of amitriptyline, trazodone and placebo. Eur J Clin Pharmacol 40: 43-48.
22. 450 2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol 15: 263-269.
23. Schulz P, Dick P, Blaschke TF, Hollister L. 1985. Discrepancies between pharmacokinetic studies of amitriptyline. Clin Pharmacokin 10: 257-268.
24. Sitsen JMA, Zivkov M. 1995. Mirtazapine: clinical profile. CNS Drugs 4: 39-48.
25. Sitsen JMA, Voortman G, Timmer CJ. 2000. Pharmacokinetics of mirtazapine and lithium in healthy male subjects. J Psychopharmacol 14(2): 172-176.
26. Timmer CJ, Sitsen JMA, Delbressine LP. 2000. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokin 38: 461-474.
27. Timmer CJ, Paanakker JE, van Hal HMJ 1996. Pharmacokinetics of mirtazapine from orally administered tablets: influence of gender, age and treatment regimen. Hum Psychopharmacol 11: 497-509.
28. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. 1998. Five distinct human cytochromes mediate amitriptyline demethylation in vitro: dominance of CYP2C19 and 3A4. J Clin Pharmacol 38: 112-121.
29. Wheatley DP, Van Moffaert M, Timmerman L, Kremer CM. 1998. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry 59: 306-312.
30. World Health Organization. 1994. Adverse Reactions Terminology (WHO-ART). World Health Organization: Geneva.